NO901315D0 - Fremgangsmaate for fremstilling av modifisert pe40. - Google Patents

Fremgangsmaate for fremstilling av modifisert pe40.

Info

Publication number
NO901315D0
NO901315D0 NO901315A NO901315A NO901315D0 NO 901315 D0 NO901315 D0 NO 901315D0 NO 901315 A NO901315 A NO 901315A NO 901315 A NO901315 A NO 901315A NO 901315 D0 NO901315 D0 NO 901315D0
Authority
NO
Norway
Prior art keywords
procedure
manufacturing modified
modified
manufacturing
Prior art date
Application number
NO901315A
Other languages
English (en)
Other versions
NO901315L (no
Inventor
Mark W Riemen
Steven M Stirdivant
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO901315D0 publication Critical patent/NO901315D0/no
Publication of NO901315L publication Critical patent/NO901315L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
NO90901315A 1989-03-22 1990-03-21 Fremgangsmaate for fremstilling av modifisert pe40. NO901315L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32721489A 1989-03-22 1989-03-22

Publications (2)

Publication Number Publication Date
NO901315D0 true NO901315D0 (no) 1990-03-21
NO901315L NO901315L (no) 1990-09-24

Family

ID=23275618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90901315A NO901315L (no) 1989-03-22 1990-03-21 Fremgangsmaate for fremstilling av modifisert pe40.

Country Status (10)

Country Link
EP (1) EP0389043A1 (no)
JP (1) JPH0798839B2 (no)
KR (1) KR0168047B1 (no)
CA (1) CA2012732C (no)
FI (1) FI901420A0 (no)
IL (1) IL93723A (no)
NO (1) NO901315L (no)
NZ (1) NZ232900A (no)
PT (1) PT93525B (no)
ZA (1) ZA902171B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
AU6733287A (en) * 1985-11-13 1987-06-02 Murphy, J.R. Cys codon-modified dna
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects

Also Published As

Publication number Publication date
CA2012732C (en) 1999-09-14
CA2012732A1 (en) 1990-09-22
KR0168047B1 (ko) 1999-01-15
EP0389043A1 (en) 1990-09-26
NZ232900A (en) 1993-08-26
FI901420A0 (fi) 1990-03-21
ZA902171B (en) 1990-12-28
IL93723A (en) 1997-02-18
KR900014598A (ko) 1990-10-24
JPH0798839B2 (ja) 1995-10-25
PT93525A (pt) 1990-11-07
NO901315L (no) 1990-09-24
IL93723A0 (en) 1990-12-23
JPH0335793A (ja) 1991-02-15
PT93525B (pt) 1996-08-30

Similar Documents

Publication Publication Date Title
NO903190L (no) Fremgangsmaate for klorering av sukrose-b-estere.
FI905882A (fi) Anordning foer maetning av ythaordheten hos byggmaterial.
NO882295D0 (no) Fremgangsmaate for fremstilling av paryledimeren.
NO894583D0 (no) Fremgangsmaate for fremstilling av celleplast.
FI906361A0 (fi) Eliminering av skadeverkan hos imidazolinonherbicider.
FI83359B (fi) Foerfarande foer framstaellning av en takskiva.
FI902336A0 (fi) Anordning foer framstaellning av en fristaoende kiselkristall.
FI905977A0 (fi) Tillaempning av oevervakningsronden hos kaernkraftverk.
FI922197A (fi) Foerfarande foer bestaemning av ytantigener hos maenskans t-celler.
NO894762L (no) Fremgangsmaate for bygging av hengebro.
FI901681A0 (fi) Foerfarande foer oekning av kaensligheten hos luminescensanalyser.
NO901509D0 (no) Fremgangsmaate for fremstilling av polyketoner.
NO901315L (no) Fremgangsmaate for fremstilling av modifisert pe40.
FI900251A0 (fi) Hjaelpmedel foer blaeddring av papper.
NO892921D0 (no) Fremgangsmaate for fremstilling av celleplast.
FI896314A0 (fi) Foerfarande foer bestaemning av troeskelvaerde hos analysmedel.
NO904732D0 (no) Fremgangsmaate for fremstilling av syntetisk wollastonitt.
FI895153A0 (fi) Anordning foer utdragning av hakkil.
FI894432A0 (fi) Anordning foer dragavlastning av ledning.
NO894285D0 (no) Framgangsmaate for framstilling av baatskrog.
FI892630A0 (fi) Foerfarande foer maetning av maengden av en i flytande form paofoerbar belaeggning.
FI892488A0 (fi) Anordning foer bestaemning av transformationsbestaendigheten hos vaegbelaeggningsprov.
FI894389A0 (fi) Anordning foer instaellning av slaeppningsvinkeln hos fanersvarvens skaer.
FI86245B (fi) Foerfarande foer tillverkning av en konserv.
FI890025A (fi) Anordning foer lottning av lottonummer.